AGIOS PHARMACEUTICALS INC
AGIONASDAQTrading Snapshot
- Day Range
- $33.30 – $33.70
- 52-Week Range
- $22.24 – $46.00
- Volume
- $3.50B
- Avg Volume
- $3.08B
- Shares Outstanding
- 59.7M
- Next Earnings
- Nov 11, 2026
Fundamentals Snapshot
- Annual Revenue
- $54M
- Last Q Revenue
- $45M
- P/E Ratio
- -4.8
- P/S Ratio
- 20.2x
- EPS (TTM)
- $-6.91
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +2.1%
Why Investors Own AGIO
- ✓High-growth profile — revenue up +49.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 34% gross margin and 11% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
AGIOS PHARMACEUTICALS INC
AGIO
StockOtter · stockotter.spaceAbout AGIOS PHARMACEUTICALS INC
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Bank of New York Mellon Corp Invests $7.37 Million in Agios Pharmaceuticals, Inc. $AGIO
Bank of New York Mellon Corp purchased a new position in Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commi
Agios Pharmaceuticals: Indication Stacking Is Creating A Commercial Flywheel
Agios is leveraging mitapivat's commercial platform across PK deficiency, thalassemia, and potentially sickle cell disease to build a durable rare-disease franchise. Thalassemia launch drove Q2 2026 mitapivat revenue to
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO). Such investors are advised to contact Daniell
Assenagon Asset Management S.A. Has $3.86 Million Stock Holdings in Agios Pharmaceuticals, Inc. $AGIO
Assenagon Asset Management S.A. lifted its stake in Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) by 54.8% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Consensus Recommendation of “Hold” by Brokerages
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO - Get Free Report) has been assigned a consensus rating of "Hold" from the ten research firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rat
AGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over Year
Agios tops Q2 revenue and earnings estimates as Aqvesme's launch and Pyrukynd sales fuel growth, while advancing its hematology pipeline.